What is the recommended treatment for mycoplasma genitalium?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Mycoplasma Genitalium

Azithromycin 1 g orally in a single dose is the recommended first-line treatment for Mycoplasma genitalium infections, as it has better efficacy against this pathogen compared to doxycycline. 1

Diagnostic Considerations

  • Testing for M. genitalium should be performed in patients with urethritis, cervicitis, or related genital tract infections 1
  • Nucleic acid amplification tests (NAATs) are the only reliable diagnostic method for detecting M. genitalium 2
  • Testing for both gonorrhea and chlamydia should also be performed in patients with suspected M. genitalium infection, as co-infections are common 1

First-Line Treatment Options

  • Azithromycin 1 g orally in a single dose is the preferred first-line treatment 1
  • Infections with M. genitalium respond better to azithromycin than to doxycycline (which has only 30-40% cure rate) 1, 2
  • Single-dose regimens have the advantage of improved compliance and allow for directly observed treatment 1

Alternative Treatment Options

If azithromycin cannot be used, alternative regimens include:

  • Doxycycline 100 mg orally twice daily for 7 days (though less effective) 1
  • Erythromycin base 500 mg orally four times daily for 7 days 1
  • Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days 1
  • Levofloxacin 500 mg orally once daily for 7 days 1
  • Ofloxacin 300 mg orally twice daily for 7 days 1

Treatment for Persistent or Resistant Infections

  • For persistent infections after azithromycin treatment, moxifloxacin 400 mg daily for 7 days is recommended as second-line therapy 3, 2
  • Moxifloxacin has been shown to be effective in eradicating persistent M. genitalium infections not responding to azithromycin 3
  • For patients with macrolide-resistant M. genitalium, an extended azithromycin regimen (500 mg on day 1, then 250 mg on days 2-5) may be more effective than the single 1 g dose 2, 4

Follow-Up Recommendations

  • Patients should be instructed to return for evaluation if symptoms persist or recur after completion of therapy 1
  • Test of cure is not routinely recommended if symptoms resolve 1
  • Patients should abstain from sexual intercourse for 7 days after single-dose therapy or until completion of a 7-day regimen 1
  • Partners should be evaluated and treated to prevent reinfection 1

Special Considerations

  • Increasing rates of macrolide resistance (>50% in some regions) are a growing concern 2, 5
  • Resistance testing for macrolide mutations, when available, can guide therapy selection 2, 6
  • Patients with persistent symptoms despite treatment are more likely to have resistant infections 3
  • Combination therapy with doxycycline followed by azithromycin or moxifloxacin (based on resistance testing) has shown improved efficacy in recent studies 4, 6

Treatment Pitfalls to Avoid

  • Inadequate treatment can lead to persistent infection and complications 3
  • Using doxycycline alone has poor efficacy (30-40% cure rate) for M. genitalium 2, 5
  • Failing to test for and treat partners can lead to reinfection 1
  • Not considering antimicrobial resistance when initial treatment fails 3, 5
  • Not addressing persistent symptoms, which may indicate treatment failure requiring alternative therapy 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

2021 European guideline on the management of Mycoplasma genitalium infections.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2022

Research

Combination Therapy for Mycoplasma genitalium, and New Insights Into the Utility of parC Mutant Detection to Improve Cure.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.